Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., ...Daha Fazla

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 4
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1046/j.1525-1438.2003.13325.x
  • Dergi Adı: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.497-504
  • Anahtar Kelimeler: chemotherapy, prognosis, recurrent cervical carcinoma, survival, GYNECOLOGIC-ONCOLOGY-GROUP, SQUAMOUS-CELL CARCINOMA, CISPLATIN PLUS IFOSFAMIDE, FIRST-LINE CHEMOTHERAPY, PHASE-II TRIAL, RANDOMIZED TRIAL, CANCER, PACLITAXEL, CYCLOPHOSPHAMIDE, BLEOMYCIN
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

The aim of this study is to identify the impact of various prognostic factors on survival in patients with recurrent carcinoma of the uterine cervix. Fifty-two patients who were treated with platinum-based chemotherapy for recurrent or metastatic disease were retrospectively evaluated. Twenty-seven patients (90%) had received pelvic radiation as primary treatment.